Synlogic (NASDAQ:SYBX) has been given a $20.00 price objective by investment analysts at HC Wainwright in a research note issued to investors on Friday. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential upside of 50.72% from the company’s current price.
Several other analysts have also recently issued reports on SYBX. Zacks Investment Research raised shares of Synlogic from a “sell” rating to a “hold” rating in a report on Saturday, January 20th. Piper Jaffray initiated coverage on shares of Synlogic in a report on Monday, January 29th. They issued an “overweight” rating and a $16.00 price target on the stock. Finally, ValuEngine cut shares of Synlogic from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. Synlogic has an average rating of “Hold” and an average price target of $20.00.
Get Synlogic alerts:
Shares of Synlogic opened at $13.27 on Friday, MarketBeat reports. The firm has a market cap of $260.64 million, a price-to-earnings ratio of -2.26 and a beta of 2.06. The company has a quick ratio of 9.82, a current ratio of 9.82 and a debt-to-equity ratio of 0.01.
Synlogic (NASDAQ:SYBX) last posted its quarterly earnings results on Tuesday, March 20th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.07. The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.11 million. analysts anticipate that Synlogic will post -2.89 EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Spark Investment Management LLC acquired a new stake in Synlogic in the fourth quarter valued at $105,000. Deutsche Bank AG raised its holdings in Synlogic by 204.0% in the fourth quarter. Deutsche Bank AG now owns 19,672 shares of the biotechnology company’s stock valued at $190,000 after acquiring an additional 13,200 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Synlogic in the fourth quarter valued at $191,000. Northern Trust Corp acquired a new stake in Synlogic in the first quarter valued at $249,000. Finally, Stanley Laman Group Ltd. acquired a new stake in Synlogic in the first quarter valued at $249,000. 55.67% of the stock is currently owned by hedge funds and other institutional investors.
Synlogic Company Profile
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.